Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS® hydromorphone ER) in patients with chronic pain

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 523-533

  Vandenbossche, Joris ^a   Richarz, Ute ^b   Richards, Henry M ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Medical Affairs   (Switzerland)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Concomitant medications; Opioid analgesics; Pain intensity; Steady state pharmacokinetic profile

Indexed keywords

HYDROMORPHONE;

ACCIDENTAL INJURY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CONSTIPATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; REPEATED DRUG DOSE; STEADY STATE; VOMITING; XEROSTOMIA;

EID: 84874953029     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S33807     Document Type: Article

References (33)

1. Turk DC, Okifuji A. Pain terms and taxonomies of pain. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica's Management of Pain. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2010:13-23.
2. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2006: with Chartbook on Trends in the Health of Americans. DHHS Publication No 2006-1232. Hyattsville, MD: National Center for Health Statistics; 2006. Available from: http://www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed June 27, 2011.
3. US Census Bureau. Preliminary Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2010 (NSTPEST2010-01). 2002 estimate. Available from: http://www.census.gov/popest/research/eval-estimates/eval-es+ 2010.html. Last accessed April 4, 2012.
4. McCarberg BH, Nicholson BD, Todd KH, Palmer T, Penles L. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther. 2008;15(4):312-320.
5. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377(9784):2226-2235.
6. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
7. Argoff CE, Silvershein DI. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602-612.
8. Herrero JF, Laird JM, López-García JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol. 2000;61(2):169-203.
9. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med. 2009;10 Suppl 2:S79-S88.
10. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage. 2003;25(2):169-178.
11. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;1:CD003447.
12. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426-439.
13. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain. 1997;72(1-2):79-85.
14. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78(4):852-857.
15. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25(5):504-515.
16. Mahler DL, Forrest WH Jr. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology. 1975;42(5):602-607.
17. Exalgo (hydromorphone HCl) extended-release tablets CII [package insert]. Hazelwood, MO: Mallinckrodt; 2010.
18. Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002;97(4):827-836.
19. Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol. 2007;7:3.
20. Moore KT, St-Fleur D, Marricco NC, et al. Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers. J Opioid Manag. 2010;6(5): 351-358.
21. Collins SL, Faura CC, Moore RA, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. Pain Symptom Manage. 1998;16(6):388-402.
22. Tan G, Jensen MP, Thornby JL, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133-137.
23. NCI Thesaurus, Hoechst Adverse Reaction Terminology System. The National Center for Biomedical Ontology BioPortal website. http://bioportal.bioontology.org/ontologies/46317/?p-terms&conceptid=Hoescht_Adverse_Reaction_Terminology_System. Adverse Reaction Terminology System. Accessed October 5, 2012.
24. Gupta S, Sathyan G. Providing constant analgesia with OROS® hydromorphone. J Pain Symptom Manage. 2007;33(Suppl 2):S19-S24.
25. Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat Care. 2009;8:14.
26. Turgeon J, Gröning R, Sathyan G, Thipphawong J, Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv. 2010;7(1):137-144.
27. Angst MS, Drover DR, Lötsch J, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology. 2001;94(1):63-73.
28. Ting N. Dose Finding in Drug Development. New York, NY: Springer; 2006.
29. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7(8):583-591.
30. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
31. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
32. Richarz U, Waechter S, Sabatowski R, Szczepanski L, Binsfeld H. Sustained Safety and Efficacy of Once-Daily Hydromorphone Extended-Release (OROS(®) hydromorphone ER) Compared with Twice-Daily Oxycodone Controlled-Release Over 52Weeks in Patients with Moderate to Severe Chronic Noncancer Pain. Pain Pract. 2012. Epub Apr 18.
33. Wallace M, Moulin DE, Rauck RL, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag. 2009;5(2):97-105.